open access

Vol 14, No 4 (2019)
Heart failure
Get Citation

Empagliflozin in heart failure — new facts. Commentary on the article: Cessation of empagliflozin treatment in a hospitalised patient with exacerbated heart failure and reduced ejection fraction. Folia Cardiol. 2019; 14(2): 199–205

Małgorzata Lelonek
DOI: 10.5603/FC.2019.0096
·
Folia Cardiologica 2019;14(4):418-419.

open access

Vol 14, No 4 (2019)
Heart failure

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Empagliflozin in heart failure — new facts. Commentary on the article: Cessation of empagliflozin treatment in a hospitalised patient with exacerbated heart failure and reduced ejection fraction. Folia Cardiol. 2019; 14(2): 199–205

Journal

Folia Cardiologica

Issue

Vol 14, No 4 (2019)

Pages

418-419

DOI

10.5603/FC.2019.0096

Bibliographic record

Folia Cardiologica 2019;14(4):418-419.

Authors

Małgorzata Lelonek

References (10)
  1. Komorowska A, Lelonek M. Przerwa w terapii empagliflozyną u pacjenta z niewydolnością serca z obniżoną frakcją wyrzutową i hospitalizacja z powodu zaostrzenia niewydolności serca. Folia Cardiol. 2019; 14(2): 199–205.
  2. Ponikowski P, Voors A, Anker S, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016; 18(8): 891–975.
  3. Zinman B, Wanner C, Lachin J, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373(22): 2117–2128.
  4. Fitchett D, Inzucchi SE, Cannon CP, et al. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial. Circulation. 2019; 139(11): 1384–1395.
  5. Inzucchi SE, Kosiborod M, Fitchett D, et al. Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control. Circulation. 2018; 138(17): 1904–1907.
  6. Claggett B, Lachin JM, Hantel S, et al. Long-term benefit of empagliflozin on life expectancy in patients with type 2 diabetes mellitus and established cardiovascular disease. Circulation. 2018; 138(15): 1599–1601.
  7. Patorno E, Pawar A, Franklin JM, et al. Empagliflozin and the risk of heart failure hospitalization in routine clinical care. Circulation. 2019; 139(25): 2822–2830.
  8. Das SR, Everett BM, Birtcher KK, et al. 2018 ACC Expert Consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2018; 72(24): 3200–3223.
  9. Seferovic PM, Ponikowski P, Anker SD, et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of The Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019 [Epub ahead of print].
  10. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease. Circulation. 2019 [Epub ahead of print]: CIR0000000000000678.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl